Search - tctmd.com

Displaying 1 - 20 of 71

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

Presentation TCT 2025

TCT 61: Comparative Analysis of Composite Outcomes for Double vs Triple Therapy in Patients with Atrial Fibrillation Post Percutaneous Coronary Intervention

Presenter: Khaled Elnaggar

October 28, 2025

Presentation TCT 2025

TCT 998: Dual Antiplatelet Therapy (DAT) versus Triple Therapy (TAT) post Percutaneous Coronary Intervention (PCI) in patients requiring Chronic Anticoagulation: Meta-analysis.

Presenter: Kanishk Aggarwal

October 27, 2025

Presentation TCT 2025

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

Antithrombotic Therapies in ACS: Atrial Fibrillation - Triple Therapy, Triple Threat!

Presenter: Usman Baber

October 26, 2025

Presentation TCT 2023

TCT 525: The Prevalence of Bleeding and Ischemic Outcomes in Patients on Triple Therapy in a Real-Practice Registry of Percutaneous Coronary Interventions

Presenter: Eva Woelders

October 25, 2023

Presentation TCT 2022

TCT 20: Relative benefit of double versus triple antithrombotic therapy in patients with atrial fibrillation randomized earlier versus later after index coronary event: Insights from the AUGUSTUS Trial

Presenter: Alexander Fanaroff

September 17, 2022

News Conference News TCT 2020

Trickier Patients, Fewer Adverse Events in High-risk PCI: Impella PROTECT III Registry

Caitlin E. Cox

October 18, 2020

Presentation TCT 2020

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

Presenter: Robert A. Byrne

October 17, 2020

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

Presentation TCT 2019

Case 3: A Patient With AF and ACS

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Case 2: A Patient With Complex Disease Who Requires Noncardiac Surgery

Presenter: Sunil Rao

September 28, 2019

Presentation TCT 2019

Case 1: A Complex Multivessel PCI in an Elderly Woman

Presenter: James Hermiller

September 28, 2019

Presentation TCT 2019

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

Welcome, Introductions, and Session Goals

Presenter: Roxana Mehran

September 28, 2019

Presentation TCT 2019

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Presenter: Dominick Angiolillo

September 27, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

TCT 61: Comparative Analysis of Composite Outcomes for Double vs Triple Therapy in Patients with Atrial Fibrillation Post Percutaneous Coronary Intervention

TCT 998: Dual Antiplatelet Therapy (DAT) versus Triple Therapy (TAT) post Percutaneous Coronary Intervention (PCI) in patients requiring Chronic Anticoagulation: Meta-analysis.

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Antithrombotic Therapies in ACS: Atrial Fibrillation - Triple Therapy, Triple Threat!

TCT 525: The Prevalence of Bleeding and Ischemic Outcomes in Patients on Triple Therapy in a Real-Practice Registry of Percutaneous Coronary Interventions

TCT 20: Relative benefit of double versus triple antithrombotic therapy in patients with atrial fibrillation randomized earlier versus later after index coronary event: Insights from the AUGUSTUS Trial

Trickier Patients, Fewer Adverse Events in High-risk PCI: Impella PROTECT III Registry

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Case 3: A Patient With AF and ACS

Case 2: A Patient With Complex Disease Who Requires Noncardiac Surgery

Case 1: A Complex Multivessel PCI in an Elderly Woman

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

Welcome, Introductions, and Session Goals

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content